Skip to main content
SpringerLink
Log in

Desmopressin (DDAVP) and hemostasis

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Desmopressin is a widely used hemostatic drug. It is a synthetic analogue of the natural hormone vasopressin, but, in contrast to vasopressin, it has no pressor activity. The effect is immediate, with two- to sixfold increases in the plasma concentrations of coagulation factor VIII, on Willebrand factor, and tissue plasminogen activator, and increases in platelet adhesiveness of comparable magnitude. Desmopressin is used in patients with mild hemophilia A, von Willebrand's disease, congenital platelet dysfunction, or acquired platelet dysfunction due to uremia or intake of such drugs as aspirin. It may also be used to reduce surgical blood loss in patients without known bleeding diathesis. Optimal hemostatic effect is achieved with a dosage of 0.3 μg/kg given intravenously. Other routes of administration are subcutaneous injection or intranasal spray. The latter proved to be efficient for home treatment of patients with bleeding disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zaoral M, Kolc J, Sorm F (1967) Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-d-amino-butyrine vasopressin, 1-deamino-8-d-lysine vasopressin and 1-deamino-8-d-arginine vasopressin. Collection Czechoslov. Chem Commun 32:1250–1257

    Google Scholar 

  2. Walter R (1976) Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neu-rohypophysial hormones by kidney preparations of various species. Biochim Biophys Acta 422:138–158

    PubMed  Google Scholar 

  3. Shimizu K, Hoshine M, Kumagawa J et al (1980) Mechanism of the prolonged antidiuretic action of DDAVP and its metabolic features. In: Share L, Yoshida S, Yagi K (eds) Antidiuretic hormone. University Park Press, Baltimore, pp 271–284

    Google Scholar 

  4. Ingram GIC (1961) Increase in antihaemophilic globulin activity following infusion of adrenaline. J Physiol 156:217–224

    PubMed  Google Scholar 

  5. Egeberg O (1963) Changes in the activity of antihemophilic A factor (f.VIII) and in the bleeding time associated with muscular exercise and adrenaline infusion. Scand J Clin Lab Invest 15:539

    PubMed  Google Scholar 

  6. Schneck S, von Kaulla KN (1961) Fibrinolysis and the nervous system. Neurology (Minneapolis) 11:959

    Google Scholar 

  7. Mannucci PM, Gagnatelli G, D'Alonzo R (1972) Stress and blood coagulation. In: Brinkhous KM, Hinnom S (eds) Thrombosis: risk factors and diagnostic approaches. Schattauer, Stuttgart, pp 105–1

    Google Scholar 

  8. Cash JD, Gader AMA, Da Costa J (1974) The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, AT III and OT in man. Br J Haematol 27:363–364

    Google Scholar 

  9. Mannucci PM, Åberg M, Nilsson IM, Robertsson B (1975) Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30:81–93

    PubMed  Google Scholar 

  10. Åberg M, Nilsson IM, Vilhardt H (1979) The release of fibrinolytic activator and factor VIII after injection of DDAVP. In: Davidsson JF (ed) Progress in chemical fibrinolysis and thrombolysis. Churchill Livingstone, Edinburgh, pp 92–97

    Google Scholar 

  11. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1:869–872

    PubMed  Google Scholar 

  12. Kobayashi I (1979) Treatment of hemophilia A and von Willebrand's disease patients with an intranasal dripping of DDAVP. Thromb Res 16:775–779

    PubMed  Google Scholar 

  13. Nilsson IM, Holmberg L, Åberg M, Vilhardt H (1980) The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrand's disease. Scand J Haematol 24:351–359

    Google Scholar 

  14. Nilsson IM, Vilhardt H, Holmberg L, Åstedt B (1982) Association between factor VIII related antigen and plasminogen activator. Acta Med Scand 211:105–1

    PubMed  Google Scholar 

  15. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) DDAVP in haemophilia. Lancet 2:1171–1172

    PubMed  Google Scholar 

  16. Kobrinsky NL, Doyle JJ, Israels EDS et al (1985) Absent factor VIII response to synthetic vasopressin analogue in nephrogenic diabetes insipidus. Lancet 1:1293–1294

    PubMed  Google Scholar 

  17. Bichet DG, Razzi M, Lonergan M et al (1988) Hemodynamic and coagulation responses to 1-desamino[8-d-arginine]vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 318:881–887

    PubMed  Google Scholar 

  18. Brenner B, Seligsohn U, Hochberg Z (1988) Normal response of factor VIII and von Willebrand factor to 1-deamino-8-d-arginine vasopressin in nephrogenic diabetes insipidus. J Clin Endocrin Metabol 67:191–193

    Google Scholar 

  19. Ohzeki T, Sunaguchi M, Tsunei M, Shinzawa T, Hanaki K, Shiraki K, Shishido H (1988) Coagulation factor responsiveness in nephrogenic diabetes insipidus. J Pediatrics 113:790

    Google Scholar 

  20. Schwartz J (1989) Vasodilation associated with V2-type vasopressin activity: findings and implications. Moll Cell Endocrinol 64:133–136

    Google Scholar 

  21. Hashemi S et al (1990) DDAVP-induced release of von Willebrand factor from endothelial cells in vitro; the effect of plasma and blood cells. Biochim Biophys Acta 1052:63–70

    PubMed  Google Scholar 

  22. Macia RA, Silver AC, Gabel RA, Campbell GK, Hanna N, DiMartino MJ (1990) Hypotension induced by vasopressin antagonists in rats: role of mast cell degranulation. Toxicol Appl Pharmacol 102:117–127

    PubMed  Google Scholar 

  23. Johns RA (1990) Desmopressin is a potent vasorelaxant of aorta and pulmonary artery isolated from rabbi and rat. Anesthesiology 72:858–864

    PubMed  Google Scholar 

  24. Murphy DJ, Joran ME (1992) Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat. Fundam Appl Toxicol 18:307–313

    PubMed  Google Scholar 

  25. Mannuci PM (1986) Desmopressin (DDAVP) for treatment of disorders of hemostasis. In: Coller BS (ed) Progress in hemostasis and thrombosis. Grune & Stratton, Orlando, pp 19–45

    Google Scholar 

  26. Nilsson IM, Mikaelsson M, Vilhardt H (1982) The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons. Scand J Haematol 29:70–74

    PubMed  Google Scholar 

  27. Stel HV, van der Kwast ThH, Veerman ECI (1983) Detection of factor VIII/coagulant antigen in human liver-tissue. Nature 303:530–532

    PubMed  Google Scholar 

  28. Wion KL, Kelly D, Summerfield JA, Tuddenham EGD, Lawn RM (1985) Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317:726–729

    PubMed  Google Scholar 

  29. Zelechowska MG, van Mourik JA, Brodniewicz-Porba T (1985) Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 317:729–730

    PubMed  Google Scholar 

  30. Howard MA, Montgomery DC, Hardisty RM (1974) Factor VIII-related antigen in platelets. Thromb Res 4:617–624

    PubMed  Google Scholar 

  31. Nachmann RL, Jaffe EA (1975) Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med 141:1101–1103

    PubMed  Google Scholar 

  32. Booyse FM, Osikowicz G, Feder S (1981) Effects of various agents on ristocetin-Willebrand factor activity in long-term cultures of von Willebrand and normal human umbilical vein endothelial cells. Thromb Haemost 46:668

    PubMed  Google Scholar 

  33. Tuddenham EGD, Lane RS, Rotblat F et al (1982) Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 52:259–267

    PubMed  Google Scholar 

  34. Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D (1978) Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood 51:267–279

    PubMed  Google Scholar 

  35. Sakariassen KS, Cattaneo M, van den Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ (1984) DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 64:229–236

    PubMed  Google Scholar 

  36. Lethagen S, Nilsson IM (1992) DDAVP-induced enhancement of platelet retention. Its dependence on plateletvon Willebrand factor and the platelet receptor GPIIb/IIIa. Eur J Haematol 49:7–13

    PubMed  Google Scholar 

  37. Lethagen S, Rugarn P (1992) The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetylsalicylic acid treatment in healthy volunteers. Thromb Haemost 67:185–186

    PubMed  Google Scholar 

  38. Mannuci PM, Canciani MT, Rota L, Donovan BS (1981) Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects, and patients with haemophilia A and von Willebrand's disease. Br J Haematol 47:283–293

    PubMed  Google Scholar 

  39. Lethagen S, Harris AS, Sjörin E, Nilsson IM (1987) Intranasal and intravenous administration of desmopressin: effect on f VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 58:1033–1036

    PubMed  Google Scholar 

  40. Köhler M, Hellstern P, Miyashita C, von Blohm G, Wenzel E (1986) Comparative study of intranasal, subcutaneous and intravenous administration of desamino-d-arginine vasopressin (DDAVP). Thromb Haemost 55:108–111

    PubMed  Google Scholar 

  41. Köhler M, Mariani G (1993) Intravenous and subcutaneous desmopressin: clinical results. In: Mariani G, Mannucci PM, Cattaneo M (eds) Desmopressin in bleeding disorders. Plenum, New York, 309–316

    Google Scholar 

  42. Harris AS, Nilsson IM, Wagner ZG, Alkner U (1986) Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci 75:1085–1088

    PubMed  Google Scholar 

  43. Harris AS, Ohlin M, Lethagen S, Nilsson IM (1988) Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci 77:337–339

    PubMed  Google Scholar 

  44. Nilsson IM, Felding P, Timberg L, Jonsson S, Harris AS (1986) Clinical experience with DDAVP. In: Ciavarella NL, Ruggeri Z, Zimmerman TS (eds) Factor VIII/von Willebrand factor. Biological and clinical advances. Proceedings of Bari Int Conference. Wichtig, Milano, pp 63–80

    Google Scholar 

  45. Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, Lindquist A (1987) Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 58:1037–1039

    PubMed  Google Scholar 

  46. Ghirardini A, Mariani G, Iacopino G, Tirindelli MC, Solinas S, Moretti T (1987) Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies. Thromb Haemost 58:896–989

    PubMed  Google Scholar 

  47. Lethagen S, Harris AS, Nilsson IM (1990) Intranasal desmopressin (DDAVP) by spray in mild haemophilia A and von Willebrand's disease type I. Blut 60:187–191

    PubMed  Google Scholar 

  48. Mannucci PM, Lombardi R, Bader R et al (1985) Heterogeneity of type-I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 66:796–802

    PubMed  Google Scholar 

  49. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS (1982) Multimeric composition of factor VIII/ von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrands disease subtypes. Blood 59:1272–1278

    PubMed  Google Scholar 

  50. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjörin E (1983) Platelet aggregation induced by 1-deamino-8-d-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease. N Engl J Med 309:816–821

    PubMed  Google Scholar 

  51. Gralnick HR, William SB, McKeown LP, Rick ME, Maissonneuve P, Jenneau C, Sultan Y (1986) DDAVP in type IIa von Willebrand's disease. Blood 67:465–468

    PubMed  Google Scholar 

  52. Holmberg L, Nilsson IM (1992) Von Willebrand's disease. Eur J Haematol 48:127–141

    PubMed  Google Scholar 

  53. Kobrinsky NL, Israels ED, Gerrard JM et al (1984) Shortening of the bleeding time by 1-deamino-8-d-arginine vasopressin in various bleeding disorders. Lancet 1:1145–1148

    PubMed  Google Scholar 

  54. Winckelman G, Augustin R (1985) Improvement of primary hemostasis by DDAVP in patients with various platelet defects. Thromb Haemost 54:12

    Google Scholar 

  55. Marti GE, Rick ME, Sidbury U, Gralnick HR (1986) DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times. Blood 68:180–184

    PubMed  Google Scholar 

  56. Mannucci PM, Vicente V, Vianello L et al (1986) Controlled trial of desmopressin in liver cirrhosis and other conditions associated with prolonged bleeding time. Blood 67:1148–1153

    PubMed  Google Scholar 

  57. Schulman S, Johnsson H, Egberg N, Blombäck M (1987) DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 45:165–174

    PubMed  Google Scholar 

  58. Kentro TB, Lottenberg R, Kitchens CS (1987) Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Am J Hematol 24:215–219

    PubMed  Google Scholar 

  59. DiMichele DM, Hathaway WE (1990) Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 33:39–45

    PubMed  Google Scholar 

  60. Kim HC, Salva KS, Fallot PL et al (1988) Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin. Thromb Haemost 59:221–224

    PubMed  Google Scholar 

  61. Nilsson IM, Lethagen S (1991) Current status of DDAVP formulations and their use. In: Lusher JM, Kessler CM (eds) Hemophilia and von Willebrand's disease in the 1990s. Elsevier Science, Amsterdam, pp 443–453

    Google Scholar 

  62. Schulman S, Johnsson H (1991) Heparin, DDAVP and the bleeding time. Thromb Haemost 65:242–244

    PubMed  Google Scholar 

  63. Lethagen S, Rugarn P, Åberg M, Nilsson IM (1990) Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms. Acta Chir Scand 156:597–602

    PubMed  Google Scholar 

  64. Jansson PA, Jubelirer SJ, Weinstein MS, Deykin D (1980) Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303:1318–1322

    PubMed  Google Scholar 

  65. Watson AJS, Koegh JAB (1982) Effect of 1-deamino-8-d-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 32:49–52

    PubMed  Google Scholar 

  66. Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS (1983) Deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8–12

    PubMed  Google Scholar 

  67. Shapiro MD, Kelleher SP (1984) Intranasal 1-deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. Am J Neophrol 4:260–261

    Google Scholar 

  68. Agnelli G, Berretini M, Cunto MD, Nenci GG (1983) Desmopressin-induced improvement of abnormal coagulation in chronic liver disease. Lancet 1:645

    Google Scholar 

  69. Burrhoughs AK, Matthews K, Quadiri M et al (1985) Desmopressin and bleeding time in patients with cirrhosis. Br Med J 291:1377–1381

    Google Scholar 

  70. Rose EH, Aledort LM (1991) Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 114:563–568

    PubMed  Google Scholar 

  71. Lethagen S, Ragnarson-Tenvall G (1993) Self-treatment with desmopressin intranasal spray in patients with bleeding disorders. Effect on bleeding symptoms and socioeconomic factors. Ann Hematol 66:257–260

    PubMed  Google Scholar 

  72. Lowe G, Pettigrew A, Middleton S, Frobes CD, Prentice CRM (1977) DDAVP in haemophilia. Lancet 2:614–615

    Google Scholar 

  73. Theiss W, Schmidt G (1978) DDAVP and von Willebrand disease: repeated administration and the behaviour of the bleeding time. Thromb Res 13:1119–1123

    PubMed  Google Scholar 

  74. Mannucci PM, Bettega D, Cattaneo M (1992) The development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 82:87–93

    PubMed  Google Scholar 

  75. Salzman EW, Weinstein MJ, Weintraub RM et al (1986) Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 314:1402–1406

    PubMed  Google Scholar 

  76. Kobrinsky NL, Letts RM, Patel LR, Israels ED, Monson RC, Schweiz N, Cheang MS (1987) 1-Desamino-8-d-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 107:446–450

    PubMed  Google Scholar 

  77. Rocha E, Llorens R, Paramo JA, Arcas R, Cuesta B, Trenor AM (1988) Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 77:1319–1323

    PubMed  Google Scholar 

  78. Hackman T, Gascoyne RD, Naiman SC et al (1989) A trial of desmopressin (1-desamino-8-d-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 321:1437–1443

    PubMed  Google Scholar 

  79. Lazenby WD, Russo I, Zadeh BJ, Zelano JA, Ko W, Lynch CC, Isom OW, Krieger KH (1990) Treatment with desmo-pressin acetate in routine artery bypass surgery to improve postoperative hemostasis. Circulation 82 [Suppl IV]: 413–419

    Google Scholar 

  80. Lo Cicero J, Massad M, Matano J (1991) Effect of desmopressin acetate on hemorrhage without identifiable cause in coronary bypass patients. Am Surg 57:165–168

    PubMed  Google Scholar 

  81. Horrow JC, van Riper DF, Strong MD, Brodsky I, Parmet JL (1991) Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 84:2063–2070

    PubMed  Google Scholar 

  82. Guay J, Reinberg C, Rivard GE, Poitras B, Mathews S, David M (1990) DDAVP does not reduce bleeding during spinal fusion for idiopathic scoliosis. Can J Anaesth 37:14

    Google Scholar 

  83. Cattaneo M, Mannucci PM (1993) Desmopressin and blood loss after cardiac surgery. Lancet 342:812

    PubMed  Google Scholar 

  84. Czer LSC, Bateman TM, Gray RJ et al (1987) Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. JACC 9:1139–1147

    PubMed  Google Scholar 

  85. Mongan PD, Hosking MP (1992) The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 77:38–46

    PubMed  Google Scholar 

  86. Gratz I, Koehler J, Olsen D et al (1992) The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 104:1417–1422

    PubMed  Google Scholar 

  87. Triplett DA (1989) Editorial: The bleeding time: neither pariah nor panacea. Arch Pathol Lab Med 113:1207–1208

    PubMed  Google Scholar 

  88. Mikaelsson M, Nilsson IM, Vilhardt H, Wiechel B (1982) Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue. Transfusion 22:229–233

    PubMed  Google Scholar 

  89. Palmer DS, Harris AS, Tittley P, Rock G (1988) Effectiveness, specificity and safety of intranasal 1-deamino-8-d-arginine vasopressin treatment of normal blood donors. Haemostasis 18:187–196

    PubMed  Google Scholar 

  90. Mannucci PM (1988) Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 72:1449–1455

    PubMed  Google Scholar 

  91. Koskimies O, Pylkkänen J, Vilska J (1984) Water intoxication in infants caused by the urine concentration test with vasopressin analogue (DDAVP). Acta Paediatr Scand 73:131–132

    PubMed  Google Scholar 

  92. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW (1985) Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 103:6–14

    PubMed  Google Scholar 

  93. Sheperd LL, Hutchinson RJ, Worden EK, Koopman CF, Coran A (1989) Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 114:470–472

    PubMed  Google Scholar 

  94. Weinstein RE, Bona RD, Altman AJ, Quinn JJ, Weisman SJ, Bartolomeo A, Rickles FR (1989) Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol 32:258–261

    PubMed  Google Scholar 

  95. Smith TJ, Gill JC, Ambrosu DR, Hathaway WE (1989) Hyponatremia and seizures in young children given DDAVP. Am J Hematol 31:199–202

    PubMed  Google Scholar 

  96. Salvatoni A, Maghnie M, Lorini R, Marni E (1990) Hyponatremia and seizures during desmopressin acetate treatment in hypothyroidism. J Pediatr 116:835–836

    Google Scholar 

  97. Binch LJC, Jacobsen MB (1992) Hyponatremia in the treatment of von Willebrand's disease (in Norwegian). Tidsskr Nor Laegeforen 112:3670–3671

    PubMed  Google Scholar 

  98. Beach PS, Beach RE, Smith LR (1992) Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake. Clin Pediatr Phila 31:566–569

    PubMed  Google Scholar 

  99. Yaouyanc G, Jonville AP, Yaouyanc-Lapalle H, Barbier P, Dutertre JP, Autret E (1992) Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis. J Toxicol Clin Toxicol 30:637–641

    PubMed  Google Scholar 

  100. Humphries KE, Siragy H (1993) Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 44:12–15

    PubMed  Google Scholar 

  101. O'Brien JR, Green PJ, Salmon G et al (1989) Desmopressin and myocardial infarction. Lancet 1:664

    PubMed  Google Scholar 

  102. van Dantzig JM, Duren DR, ten Cate JW (1989) Desmopressin and myocardial infarction. Lancet 1:664

    PubMed  Google Scholar 

  103. Bond L, Bevan DU (1988) Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 318:121

    Google Scholar 

  104. Mannucci PM, Lusher JM (1989) Desmopressin and thrombosis. Lancet 2:675–676

    PubMed  Google Scholar 

  105. Mannucci PM, Carlsson S, Harris AS (1994) Desmopressin, surgery and thrombosis. Thromb Haemost 71:154–155

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Coagulation Disorders, University of Lund, Malmö General Hospital, S-21401, Malmö, Sweden

    S. Lethagen

Authors
  1. S. Lethagen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lethagen, S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 69, 173–180 (1994). https://doi.org/10.1007/BF02215950

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02215950

Key words

Search

Navigation